147 related articles for article (PubMed ID: 20136626)
1. Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.
Reikvam H; Olsnes AM; Gjertsen BT; Ersvar E; Bruserud Ø
Crit Rev Oncog; 2009; 15(1-2):1-41. PubMed ID: 20136626
[TBL] [Abstract][Full Text] [Related]
2. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
Jin Y; Lu Z; Ding K; Li J; Du X; Chen C; Sun X; Wu Y; Zhou J; Pan J
Cancer Res; 2010 Mar; 70(6):2516-27. PubMed ID: 20215516
[TBL] [Abstract][Full Text] [Related]
3. Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target.
Zhou J; Ching YQ; Chng WJ
Oncotarget; 2015 Mar; 6(8):5490-500. PubMed ID: 25823927
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization by 4-hydroxyphenyl retinamide-induced NF-κB inhibition in acute myeloid leukemia cells.
Zhang H; Xu H; Zhang R; Zhao X; Liang M; Wei F
Cancer Chemother Pharmacol; 2020 Aug; 86(2):257-266. PubMed ID: 32696214
[TBL] [Abstract][Full Text] [Related]
5. [NF-κB activity in myeloid leukemia stem cells].
Kagoya Y
Rinsho Ketsueki; 2015 Apr; 56(4):384-91. PubMed ID: 25971268
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics.
Reikvam H
Cells; 2020 Jul; 9(7):. PubMed ID: 32664684
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.
Bruserud Ø; Reikvam H
Expert Opin Ther Targets; 2010 Nov; 14(11):1139-42. PubMed ID: 20942744
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of microRNA-125b inhibits human acute myeloid leukemia cells invasion, proliferation and promotes cells apoptosis by targeting NF-κB signaling pathway.
Wang Y; Tang P; Chen Y; Chen J; Ma R; Sun L
Biochem Biophys Res Commun; 2017 Jun; 488(1):60-66. PubMed ID: 28478034
[TBL] [Abstract][Full Text] [Related]
9. Constitutive NF-κB activation in AML: Causes and treatment strategies.
Bosman MC; Schuringa JJ; Vellenga E
Crit Rev Oncol Hematol; 2016 Feb; 98():35-44. PubMed ID: 26490297
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia.
Jenkins C; Hewamana S; Gilkes A; Neelakantan S; Crooks P; Mills K; Pepper C; Burnett A
Br J Haematol; 2008 Dec; 143(5):661-71. PubMed ID: 19036014
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies.
Fuchs O
Curr Mol Pharmacol; 2010 Nov; 3(3):98-122. PubMed ID: 20594187
[TBL] [Abstract][Full Text] [Related]
12. NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.
Breccia M; Alimena G
Expert Opin Ther Targets; 2010 Nov; 14(11):1157-76. PubMed ID: 20858024
[TBL] [Abstract][Full Text] [Related]
13. TLR4/NF-κB axis induces fludarabine resistance by suppressing TXNIP expression in acute myeloid leukemia cells.
Huy H; Kim TD; Kim WS; Kim DO; Byun JE; Kim MJ; Park YJ; Yoon SR; Noh JY; Lee J; Lee KH; Choi I; Jung H
Biochem Biophys Res Commun; 2018 Nov; 506(1):33-40. PubMed ID: 30336978
[TBL] [Abstract][Full Text] [Related]
14. The TAK1-NF-κB axis as therapeutic target for AML.
Bosman MC; Schepers H; Jaques J; Brouwers-Vos AZ; Quax WJ; Schuringa JJ; Vellenga E
Blood; 2014 Nov; 124(20):3130-40. PubMed ID: 25287709
[TBL] [Abstract][Full Text] [Related]
15. Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.
Kagoya Y; Yoshimi A; Kataoka K; Nakagawa M; Kumano K; Arai S; Kobayashi H; Saito T; Iwakura Y; Kurokawa M
J Clin Invest; 2014 Feb; 124(2):528-42. PubMed ID: 24382349
[TBL] [Abstract][Full Text] [Related]
16. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).
Omsland M; Bruserud Ø; Gjertsen BT; Andresen V
Oncotarget; 2017 Jan; 8(5):7946-7963. PubMed ID: 27974700
[TBL] [Abstract][Full Text] [Related]
17. Oroxylin A, a natural compound, mitigates the negative effects of TNFα-treated acute myelogenous leukemia cells.
Li H; Lu N; Yu X; Liu X; Hu P; Zhu Y; Shen L; Xu J; Li Z; Guo Q; Hui H
Carcinogenesis; 2018 Oct; 39(10):1292-1303. PubMed ID: 29346508
[TBL] [Abstract][Full Text] [Related]
18. ZNF460-regulated COMMD7 Promotes Acute Myeloid Leukemia Proliferation Via the NF-κB Signaling Pathway.
Shao X; Zhong L; Chu X; Wan P; Chen S; Zhou Z; Zhang H; Wang M; Liu B
Int J Med Sci; 2023; 20(4):520-529. PubMed ID: 37057209
[TBL] [Abstract][Full Text] [Related]
19. Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling.
Li J; Volk A; Zhang J; Cannova J; Dai S; Hao C; Hu C; Sun J; Xu Y; Wei W; Breslin P; Nand S; Chen J; Kini A; Zhu J; Zhang J
Oncotarget; 2017 Jan; 8(5):8420-8435. PubMed ID: 28039479
[TBL] [Abstract][Full Text] [Related]
20. [Role of NF-κB inhibitor in Acute Myeloid Leukemia].
Wang WL; Xu QZ; Mu XH; Wang L; Zhang LY; Xu J; Gao YD; Cheng T; Yuan WP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1622-1626. PubMed ID: 28024466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
